References
- GassJDBlodiBAIdiopathic juxtafoveal retinal telangiectasis. Update of classification and follow-up studyOphthalmology1993100153615468414413
- EngelbrechtNEAabergTMJrSungJLewisMLNeovascular membranes associated with idiopathic juxtafoveolar telangiectasisArch Ophthalmol200212032032411879135
- YannuzziLABardalAMFreundKBChenKJEandiCMBlodiBidiopathic macular telangiectasiaArch Ophthalmol200612445046016606869
- SnyersBVerougstraeteCPostelmansLLeysAHykinPPhotodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasisAm J Ophthalmol200413781281915126144
- Charbel IssaPFingerRPHolzFGSchollHPEighteen-month follow-up of intravitreal bevacizumab in type 2idiopathic macular telangiectasiaBr J Ophthalmol20089294194518577646
- RuysJDe LaeyJJVanderhaeghenYVan AkenEHIntravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membraneEye2007211433143417693997
- MandalSVenkateshPAbbasZVohraRGargSIntravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasiaGraefes Arch Clin Exp Ophthalmol20072451825182917345090
- JorgeRCostaRACalucciDScottIUIntravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasisGraefes Arch Clin Exp Ophthalmol20072451045104817136357
- MoonSJBergerASTolentinoMJMischDMIntravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telaniectasisOphthalmic Surg Lasers Imaging20073816416617396701
- RishiPShroffDRishiECombined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane associated with type 2 idiopathic macular telangiectasiaGraefes Arch Clin Exp Ophthalmol200824661962118193448